Page 9 - Study Evaluating News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Ready or Not 2021: Protecting the Public’s Health Against Diseases, Disasters, and Bioterrorism This report measured states’ performance on 10 key emergency preparedness indicators placing 20 states and the District of Columbia in a high level of preparedness tier, 15 states in a middle preparation tier and 15 states in a low degree of preparation tier. The report analysis found room for improvement in every jurisdiction. Trust for America’s Health Could the Bioweapons Treaty Be Another Tool for Addressing Pandemics? In light of COVID-19, perhaps now is the right time to revisit the 46-...

Teleflex Completes Enrollment in CTO-PCI IDE Study Enrollment Completed Ahead of Schedule in Study Evaluating the Performance of Teleflex Specialty Catheters and Coronary Guidewires in Patients Undergoing Chronic Total Occlusion Percutaneous Coronary Interventions WAYNE, Pa., Feb. 17, 2021 (GLOBE NEWSWIRE) — Teleflex Incorporated (NYSE: TFX), a leading global provider of medical technologies, today announced the completion of patient enrollment in a clinical study evaluating the performance of Teleflex specialty catheters and coronary guidewires in Chronic Total Occlusion (CTO) percutaneous...

SparingVision Conference Participation in H1 2021 SparingVision Conference Participation in H1 2021 Paris, February 16, 2021 - SparingVision ("the Company"), a genomic medicine company developing vision saving treatments for ocular diseases, announces the conferences that its management team will be participating in in the first half of 2021. OIS Gene Therapy Innovation Showcase , 18 February Gene Therapy Outlook panel, Prof. José Alain Sahel, scientific co-founder (2:30-3:30 PM EST) 4th Annual Gene Therapy for Rare Disorders , 22-25 February , Dr Dan Chung, Chief Medical Officer, (Feb 22, 3...

European Commission Approves AbbVie's RINVOQ™ (Upadacitinib) for the Treatment of Psoriatic Arthritis and Ankylosing Spondylitis - RINVOQ (15 mg, once daily) is the first oral, once-daily, selective and reversible JAK inhibitor approved for three adult rheumatic indications in the European Union: rheumatoid arthritis, psoriatic arthritis and ankylosing spondylitis[1,2] - Approval is supported by data from three pivotal clinical studies in psoriatic arthritis and ankylosing spondylitis where RINVOQ met all primary and met key secondary endpoints with a safety profile consistent with that see...